GGrantIndex
← Leaderboards

Kathryn A Phillips

University Of California San Francisco

$14,137,510
Attributed
$14,137,510
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.2M · FY200525
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$19,190,360 · 9

By mechanism

R01$12,883,312 · 6
P01$6,307,048 · 3

Top collaborators

No co-investigators on record.

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Policies

Research focus

PoliciesMalignant NeoplasmsComplexAdoptedFundingPolicy AnalysisInnovationProviderEconomic ValueStructureResearch PersonnelGenomicsClinical CareResourcesHealth PolicyPreferenceBaseCostGrantInterviewIndustryEconomic OutcomeCost EffectivenessEconomic Evaluation

Grant awards (34)

BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING$852,472
R01 · FY2025 · HG · contact PI
BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING$918,686
R01 · FY2024 · HG · contact PI
BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING$937,434
R01 · FY2023 · HG · contact PI
BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING$937,434
R01 · FY2022 · HG · contact PI
BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING$953,132
R01 · FY2021 · HG · contact PI
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions$595,726
R01 · FY2020 · CA · contact PI
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions$348,554
R01 · FY2020 · CA · contact PI
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions$631,965
R01 · FY2019 · CA · contact PI
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions$646,833
R01 · FY2018 · CA · contact PI
Risk-Benefit Trade-Offs for Whole Genome Sequencing$490,805
R01 · FY2016 · HG · contact PI
Risk-Benefit Trade-Offs for Whole Genome Sequencing$559,968
R01 · FY2015 · HG · contact PI
Risk-Benefit Trade-Offs for Whole Genome Sequencing$572,113
R01 · FY2014 · HG · contact PI
Risk-Benefit Trade-Offs for Whole Genome Sequencing$338,529
R01 · FY2014 · HG · contact PI
Risk-Benefit Trade-Offs for Whole Genome Sequencing$507,770
R01 · FY2013 · HG · contact PI
Personalized Medicine for Colorectal and Breast Cancer$1,495,702
P01 · FY2010 · CA · contact PI
DISSEMINATION AND ADMINISTRATION$406,864
P01 · FY2010 · CA · contact PI
EVIDENCE BASE FOR PERSONALIZED MEDICINE TRANSLATION$60,831
P01 · FY2010 · CA · contact PI
Personalized Medicine for Colorectal and Breast Cancer$1,789,311
P01 · FY2009 · CA · contact PI
DISSEMINATION AND ADMINISTRATION$378,010
P01 · FY2009 · CA · contact PI
EVIDENCE BASE FOR PERSONALIZED MEDICINE TRANSLATION$61,245
P01 · FY2009 · CA · contact PI
Personalized Medicine for Colorectal and Breast Cancer$1,767,837
P01 · FY2008 · CA · contact PI
DISSEMINATION AND ADMINISTRATION$303,894
P01 · FY2008 · CA · contact PI
EVIDENCE BASE FOR PERSONALIZED MEDICINE TRANSLATION$43,354
P01 · FY2008 · CA · contact PI
Screening for Colorectal Cancer: An Integrated Approach$331,659
R01 · FY2007 · CA · contact PI
Screening for Colorectal Cancer: An Integrated Approach$124,243
R01 · FY2007 · CA · contact PI
Screening for Colorectal Cancer: An Integrated Approach$590,879
R01 · FY2006 · CA · contact PI
Screening for Colorectal Cancer: An Integrated Approach$87,219
R01 · FY2006 · CA · contact PI
Screening for Colorectal Cancer: An Integrated Approach$623,621
R01 · FY2005 · CA
Screening for Colorectal Cancer: An Integrated Approach$630,532
R01 · FY2004 · CA
USE OF CANCER SCREENING IN A MANAGED CARE ENVIRONMENT$247,749
R01 · FY2002 · CA
USE OF CANCER SCREENING IN A MANAGED CARE ENVIRONMENT$274,174
R01 · FY2001 · CA
UTILIZATION AND COST EFFECTIVENESS OF NEW HIV TESTS$156,198
R01 · FY2001 · AI
USE OF CANCER SCREENING IN A MANAGED CARE ENVIRONMENT$294,875
R01 · FY2000 · CA
UTILIZATION AND COST EFFECTIVENESS OF NEW HIV TESTS$230,742
R01 · FY2000 · AI